Product Code: RP-ID-10070561 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10070561
Market Overview:
Monoclonal Antibodies (MABs) Market Segmentation by Type (Human MAB, Humanized MAB, Chimeric MAB, and Murine MAB); by Application (Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, and Others); by End User (Hospitals, Private Clinics, Online Pharmacy, Research Institutes, and Others)-Global Demand Analysis & Opportunity Outlook 2031
Global Monoclonal Antibodies (MABs) Market Highlights Over 2022 - 2031
The global monoclonal antibodies (MABs) market is estimated to garner around USD 450 billion in revenue by 2031 by growing at a CAGR of nearly 14% over the forecast period, i.e., 2022 – 2031. The growth of the market can be attributed to the increasing prevalence of cancer, rising demand for cost-efficient biosimilar monoclonal antibodies, and an increase in R&D activities. For instance, according to the World Health Organization (WHO), the total number of deaths due to cancer accounted for nearly 10 million in 2020, which was nearly one in six deaths. Additionally, a rise in awareness among patients & physicians is expected to boost the demand for monoclonal antibodies in the upcoming years.
 Market - IG.jpg)
CLICK TO DOWNLOAD A SAMPLE REPORT
The COVID-19 pandemic had a positive impact on the monoclonal antibodies (MABs) market owing to the development of monoclonal antibodies therapy to treat COVID-19. The recognition of the urgent need for treatments available on a global scale has encouraged the rapid development of a large number of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) neutralizing monoclonal antibodies. This is further increasing the adoption of MABs. Moreover, presence of well-established healthcare infrastructure, government support in infection control & management, and an increase in incidence of lifestyle associated diseases are the other factors predicted to fuel market growth.
However, stringent regulatory policies for approval process, poor demand in under-developed countries, and potential side effects of these drugs are the key factors restraining the growth of the market.
The market is segmented by application into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, and others, out of which, the cancer segment is anticipated to hold the major share over the forecast period. The growth can be attributed to increasing cancer cases, and rise in the adoption of monoclonal antibodies in cancer treatment. In addition to these, improving healthcare reimbursement policies, potential pipeline candidates, and increasing awareness among the patient population regarding cancer treatment procedures are further driving the growth of the segment.
Global Monoclonal Antibodies (MABs) Market Regional Synopsis
Regionally, the global monoclonal antibodies (MABs) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America region is estimated to hold the largest share of the market over the forecast period on the back of rising number of product launches, and the increasing prevalence of chronic diseases. For instance, according to National Cancer Institute, in 2020, there were an estimated number of 1,806,590 new cancer cases in the United States, and nearly 606,520 people died from the disease. Additionally, rising funding by the government to increase research and development activities for cancer is expected to also boost the market growth of the region.
On the other hand, the Europe region is expected to witness significant market growth owing to favorable health reimbursement and easy approval, and the launch of biosimilar monoclonal antibodies.
Furthermore, the Asia-Pacific region is predicted to be the fastest-growing region in the global MABs market on the back of the rising incidences of arthritis and inflammatory diseases, increasing geriatric population, and growing preference for biosimilar MABs.
Market Segmentation
Our in-depth analysis of the global monoclonal antibodies (MABs) market includes the following segments:
By Type
-
Human MAB
-
Humanized MAB
-
Chimeric MAB
-
Murine MAB
By Application
-
Cancer
-
Autoimmune Diseases
-
Inflammatory Diseases
-
Infectious Diseases
-
Others
By End-User
-
Hospitals
-
Private Clinics
-
Online Pharmacy
-
Research Institutes
-
Others
Growth Drivers and Challenges Impacting the Growth of the Global Monoclonal Antibodies (MABs) Market
Growth Drivers
-
Increase in prevalence of cancer and chronic diseases
-
Rise in awareness among patients & physicians related to monoclonal antibodies (MABs) therapy
Challenges
-
Potential side effects of these drugs
-
Poor demand in under-developed countries
-
Stringent regulatory policies for approval process
Key Companies Dominating the Global Monoclonal Antibodies (MABs) Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global monoclonal antibodies (MABs) market that are included in our report are Amgen Inc., AstraZeneca, Bayer AG, Merck KGaA, Eli Lilly and Company, GlaxoSmithKline plc., BioMed Central Ltd., Novartis AG, American Medical Association, Elabscience Biotechnology Inc., and others.
Latest Developments in the Global Monoclonal Antibodies (MABs) Market:
-
February 2022: Eli Lilly and Company, announced the release of an Emergency Use Authorization (EUA) for bebtelovimab, an antibody issued by the U.S. Food and Drug Administration (FDA) that displays neutralization against the Omicron variant.
-
December 2021: GlaxoSmithKline plc and Vir Biotechnology, Inc. announced an update to preclinical data on bioRxiv, a preprint server, demonstrating that sotrovimab, an investigational monoclonal antibody, retains in-vitro activity against the full known Omicron spike protein.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- Amgen Inc.
- AstraZeneca
- Bayer AG
- Merck KGaA
- Eli Lilly and Company
- GlaxoSmithKline plc.
- BioMed Central Ltd.
- Novartis AG
- American Medical Association
- Elabscience Biotechnology Inc.
Related Reports
Proof of Quality & Reliability
